Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
The most effective method to Decisively Plan Your Nursing Profession for the Best Compensation Results - 2FACT FOCUS: Trump sows confusion on number of childhood vaccinations
- 3Monetary Strengthening: Assuming Command over Your Cash
- 4Would you ever turn to AI for companionship? 6% of Americans say they could — or already have.
- 5Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- Exploring the Gig Economy: Examples from Consultants
- Vote In favor of Your Favored Sort Of Bevarage
- 6 Agreeable Earphones To Wear
- IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports
- Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- Step by step instructions to Pick the Right Dental specialist for Your Teeth Substitution
- Which Espresso Do You Like Best? Vote
- A hunger for new experiences Narratives: Motivating Travel and Experience
- Italy now recognizes the crime of femicide and punishes it with life in prison
